

ASX / Media Release

21 January 2011

RHT: Resonance Health Gains Worldwide Exclusive License

The Board of Resonance Health is pleased to announce it has signed a Heads of Agreement for the exclusive world-wide license for a new imaging technology developed at the University College of London. This announcement further positions Resonance Health as an international leader in the imaging diagnostic market and provides significant potential for the Company.

The Equilibrium Contrast Imaging technology has potential applications in the non invasive measurement of diffuse fibrosis in tissues such as the liver (where fibrosis can be caused by chronic hepatitis or alcohol abuse) and the heart (where diffuse fibrosis plays a key role in cardiac diseases such as hypertension, cardiomyopathies and valve disease, leading to heart failure and death) as well as the monitoring of amyloid deposits in tissues in amyloidosis diseases.

This technology provides a method of diagnosing disease and monitoring the progression of disease in a repeatable, non-invasive way. Research projects to expand the potential commercial application for this technology are in progress. An international patent has been lodged.

UK pharmaceutical company GlaxoSmithKline (GSK) has entered a research agreement with University College London to further develop the Equilibrium Contrast Imaging technology for potential use in clinical trials for amyloidosis therapies. Resonance Health, through its established image analysis laboratory, is ideally suited to provide imaging services to GSK through their clinical trial program, using this new technology.

This technology complements the Company's other research and development activities in the development of imaging technologies for the measurement of liver fibrosis and liver fat and the provision of imaging services for clinical trials.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Colin McDonald
Company Secretary
T: +61 8 9286 5300
E: colinm@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.